First National Bank of Omaha Acquires Shares of 73,248 Enovis Corporation $ENOV
First National Bank of Omaha has acquired 73,248 shares of Enovis Corporation, a medical technology company, for approximately $2.22 million, representing a new position and 0.13% ownership. Institutional investors now hold about 98.45% of Enovis stock, while analysts have a "Moderate Buy" rating with an average target price significantly higher than current trading levels. Insider activity shows mixed signals, with a director buying shares and an EVP selling.
Enovis (ENOV) Expected to Announce Quarterly Earnings on Thursday
Enovis (ENOV) is scheduled to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts anticipating $0.81 EPS and $584.3 million in revenue. The stock opened at $22.08, reflecting a 2.1% increase, and has a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $46.71. Insider transactions show recent buying and selling activity, while institutional ownership stands at a high 98.45%.
Enovis Corporation (ENOV) Stock Analysis: Captivating 107% Upside Potential Amid Strong Buy Ratings
Enovis Corporation (ENOV), a medical device company, shows a significant 107.12% upside potential, with analysts issuing 11 "buy" ratings despite recent stock declines and negative EPS and ROE. The company's robust free cash flow and strategic market positioning in orthopedic solutions are highlighted as key strengths, suggesting a strong recovery and growth trajectory for patient investors. Technical indicators also point to an oversold stock, potentially offering a buying opportunity.
Impax Asset Management Group plc Acquires 100,000 Shares of Enovis Corporation $ENOV
Impax Asset Management Group plc increased its stake in Enovis Corporation (NYSE:ENOV) by 47.5% in the third quarter, acquiring an additional 100,000 shares to own a total of 310,630 shares valued at $9.425 million. This report also details other hedge fund activities, insider transactions, and analyst ratings for Enovis, which highlight a "Moderate Buy" consensus and an average price target of $46.71. The company's stock trades at $22.77, with a market capitalization of $1.30 billion.
Enovis (ENOV) Valuation Check As Positive Analyst Views Follow A Difficult Year
Enovis (ENOV) is attracting renewed attention due to its presentation at the Annual MedTech conference, despite a challenging prior year with significant share price decline. Analysts view the stock as undervalued, with a fair value of $45.09 against a current price of $22.80, based on expected operational improvements and earnings growth. However, this positive outlook depends on successful integration of acquisitions and timely tech launches, with potential risks if delays occur.
Evercore ISI Bullish on Enovis (ENOV) Despite Weak Share Price Momentum
Evercore ISI has reiterated an 'Outperform' rating for Enovis (ENOV) with a $40 price target, despite the stock's significant decline in 2025 and subsequent weak share price momentum. The firm's bullish stance is driven by an 11% EPS beat, improved FY26 cash flow projections, and the company's multi-segment orthopedic strategy. BTIG also initiated coverage with a 'Buy' rating and a $41 price target, seeing an attractive entry point for investors.
Evercore ISI Bullish on Enovis (ENOV) Despite Weak Share Price Momentum
Evercore ISI maintains a 'Outperform' rating on Enovis (ENOV) with a $40 price target, despite the stock's 50% decline over the past year and a recent revenue miss. The firm remains bullish due to an implied 11% EPS beat from high-margin reconstructive operations and projected FY26 cash flow improvement. BTIG also initiated coverage with a 'Buy' rating and a $41 price target, highlighting the company's multi-segment orthopedic strategy and an attractive entry point for investors.
Universal Beteiligungs und Servicegesellschaft mbH Lowers Stock Position in Enovis Corporation $ENOV
Universal Beteiligungs und Servicegesellschaft mbH significantly reduced its stake in Enovis Corporation ($ENOV) by 99.0% in Q3, selling 888,425 shares. Despite this, institutional ownership remains high at 98.45%, and analysts maintain a "Moderate Buy" rating with a consensus target price of $46.71, suggesting potential upside from its current price of approximately $21.78. The company recently reported better-than-expected earnings of $0.75 EPS against an estimate of $0.67 and revenue of $548.9 million, yet it still faces profitability challenges indicated by a negative net margin.
Medical technology company Enovis to attend BTIG MedTech, digital health event
Enovis (NYSE: ENOV), a medical technology company, announced its management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026. This announcement, which contained no new financial data, led to a slight negative market reaction for ENOV stock, although past conference participations have shown mixed historical impacts. The company will discuss developments, strategy, and growth initiatives, with investors able to access information via Enovis's investor relations website.
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Viridian Therapeutics (VRDN) and Enovis (ENOV)
This article highlights bullish sentiments from financial analysts on three healthcare companies: Alphatec Holdings (ATEC), Viridian Therapeutics (VRDN), and Enovis (ENOV). Analysts from Canaccord Genuity and Wedbush maintained Buy ratings for these companies, setting price targets that suggest significant upside potential from their current stock levels. The report includes specific analyst ratings, price targets, and average consensus ratings for each company.
Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Enovis Corporation announced its management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026. Enovis, a medical technology company, specializes in developing solutions that improve patient outcomes and restore motion. The company routinely communicates material information to investors via SEC filings, press releases, webcasts, and its Investor Relations website.
CCORF Maintains Enovis Corp(ENOV.US) With Buy Rating, Maintains Target Price $50
CCORF analyst Caitlin Cronin has reiterated a "buy" rating for Enovis Corp (ENOV.US), maintaining a target price of $50. According to TipRanks data, the analyst has a 55.7% success rate and an average return of 13.4% over the past year. This rating is based on an independent third-party analysis provided by TipRanks, which tracks financial analysts' recommendations and performance.
Enovis Corporation (NYSE:ENOV) Given Average Rating of "Moderate Buy" by Analysts
Enovis Corporation (NYSE:ENOV) has received an average "Moderate Buy" rating from analysts, with a 1-year average price target of $46.71, significantly higher than its recent open of $22.69. The company surpassed its last quarter's earnings and revenue estimates and set strong FY2025 guidance. Insider buying and substantial institutional ownership further highlight potential confidence in the stock.
Enovis Corp (ENOV) Trading Down 3.36% on Jan 28
Enovis Corp (ENOV) shares dropped 3.36% on January 28, reaching an intraday low of $21.19. The stock is currently 56.09% below its 52-week high and barely above its 52-week low. Wall Street analysts forecast an average target price of $45.45, implying a 114.00% upside, while GuruFocus estimates a fair value of $62.64, suggesting a 194.9% upside.
Enovis schedules Feb. 26 webcast on 2025 financial results
Enovis (NYSE: ENOV) will host a conference call and live webcast on February 26, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results. An earnings press release will be issued earlier that morning, and details for accessing the webcast and dial-in information for the call are available on the company's investor relations website. This announcement follows a consistent pattern of quarterly earnings call notices and is expected to have a modest impact on the stock price, in line with historical trends for similar events.
Enovis stock hits 52-week low at $22.93 amid challenging year
Enovis Corporation's stock has hit a new 52-week low at $22.93, marking a significant 53.6% decline from its high and a 50.18% decrease over the past year. Despite revenue growth, the company has not been profitable, reflecting market volatility and investor concerns. However, analysts maintain an optimistic outlook, with Buy ratings and price targets suggesting potential profitability this year.
Enovis stock hits 52-week low at $22.93 amid challenging year By Investing.com
Enovis Corporation's stock has plummeted to a 52-week low of $22.93, representing a 53.6% decline from its high, despite analysts maintaining optimistic ratings and price targets. The company, which is currently undervalued according to InvestingPro data, has experienced a challenging year with a 50.18% decrease in stock value and unprofitability over the last twelve months, although revenue grew by 11.57%. Recent developments include new analyst coverage with "Buy" ratings and leadership changes aimed at enhancing operational efficiency.
Enovis stock hits 52-week low at $22.93 amid challenging year
Enovis Corp's stock has hit a new 52-week low of $22.93, marking a 53.6% decline from its high, despite 11.57% revenue growth. The company has not been profitable in the last year, reflecting market challenges and investor concerns. Analysts, however, remain optimistic, predicting profitability this year with price targets ranging from $33 to $55.
Enovis Corp (ENOV) Shares Down 3.93% on Jan 23
Shares of Enovis Corp (ENOV) dropped 3.93% on January 23, reaching an intraday low of $22.50. Despite the dip, analyst forecasts suggest a potential upside of 100.90% from the current price, with an average target price of $45.45. GuruFocus also estimates a fair value of $62.64 for ENOV, indicating an even larger potential upside.
Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th
Enovis Corporation (NYSE: ENOV) announced it will host an investor conference call and live webcast on February 26th, 2026, at 8:30 a.m. Eastern Time to discuss its fourth quarter and full year 2025 financial results. The company, an innovation-driven medical technology growth company, will issue an earnings press release earlier that morning. Investors can access the webcast and a related presentation via the "Investors" section of Enovis' website.
Assessing Enovis (ENOV) Valuation After Recent Weak Share Price Performance
Enovis (ENOV) has experienced significant share price declines recently but shows potential for undervaluation. Trading at a Price-to-Sales ratio of 0.6x compared to an estimated fair P/S of 1.8x, and with a DCF fair value of US$63.92 against a US$23.68 share price, the company appears to be undervalued. However, investors are cautioned to consider the company's US$1,367.36m net loss and multi-year negative shareholder returns as potential risks.
Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th
Enovis Corporation announced it will host an investor conference call and live webcast on Thursday, February 26th, 2026, at 8:30 a.m. Eastern Time to discuss its financial results for the fourth quarter and full year 2025. An earnings press release will be issued earlier that morning. Investors can access the webcast and related presentation on the "Investors" section of Enovis' website, with dial-in information provided for the live call.
Enovis Corporation (ENOV): Orthopedic Innovation and Growth Potential Drive Analyst Confidence
Enovis Corporation (ENOV) is positioned for growth in the orthopedic market, with analysts recognizing its innovation and potential. BTIG initiated Buy coverage with a $41 price target, citing consistent revenue growth in its Reconstruction and Prevention & Recovery segments and expected acceleration in 2026 due to new product launches. UBS, while maintaining a Buy rating, adjusted its price target to $50 from $57, projecting sales growth and an acceleration from new product launches.
Enovis Corporation (ENOV): Orthopedic Innovation and Growth Potential Drive Analyst Confidence
Enovis Corporation (ENOV) is gaining analyst confidence due to its strong orthopedic innovation and growth potential. BTIG initiated coverage with a Buy rating and a $41 price target, anticipating accelerated growth from new product launches in 2026, especially in its higher-growth Reconstruction business. UBS also maintained a Buy rating, though it slightly lowered its price target, based on solid sales projections and the expectation of increased growth from new product launches like ARVIS.
Enovis Corporation (ENOV): Orthopedic Innovation and Growth Potential Drive Analyst Confidence
Enovis Corporation (ENOV) is gaining analyst confidence due to its orthopedic innovation and growth potential. BTIG initiated coverage with a Buy rating and a $41 price target, citing consistent revenue growth and new product launches across various segments. UBS also maintains a Buy rating though it slightly lowered its price target, forecasting accelerated growth fueled by new product introductions.
Assessing Enovis (ENOV) Valuation After Recent Weak Share Price Performance
Enovis (ENOV) has experienced a significant share price decline recently but saw a 2.6% gain in the latest session. Despite weak market performance, the company appears undervalued based on its Price-to-Sales ratio of 0.6x compared to an estimated fair P/S of 1.8x and a DCF fair value of US$63.92 against a US$23.68 share price. Investors are urged to consider current risks, such as net losses and negative shareholder returns, while also looking at future growth potential.
Enovis Corporation (ENOV): A Bull Case Theory
This article summarizes a bullish thesis on Enovis Corporation (ENOV), highlighting its dual-engine model in musculoskeletal healthcare, combining surgeon-driven implants with prevention and recovery products. The company focuses on specialization and targeted M&A to compete with larger rivals, despite elevated leverage. The investment case depends on successful integration, surgeon adoption, and disciplined capital allocation.
Enovis Corporation (ENOV): A Bull Case Theory
This article summarizes a bullish thesis on Enovis Corporation (ENOV), highlighting its dual-engine economic model in musculoskeletal healthcare, combining high-margin implant sales with lower-margin prevention and recovery products. The company focuses on specialization, M&A, and R&D for growth, despite competing with larger incumbents and facing financial leverage. The investment case relies on successful integration, surgeon adoption, and disciplined capital allocation.
A Look At Enovis (ENOV) Valuation After Naming Oliver Engert As Chief Administrative Officer
Enovis (ENOV) has appointed Oliver Engert as Chief Administrative Officer, a strategic move following a significant decline in shareholder returns over the past year. Despite recent stock pressure, the article suggests Enovis is undervalued with a fair value of $45.45 against its current $24.66, based on expectations of improved earnings and deleveraging through operational efficiency initiatives. This valuation, however, depends on the company's ability to manage acquisition integration, tariffs, and regulatory costs.
March 20th Options Now Available For Enovis (ENOV)
New options for Enovis Corp (ENOV) with a March 20th expiration date are now trading. A specific call contract at the $25.00 strike price is highlighted, suggesting a potential 2.55% return for investors who purchase ENOV shares at $24.72 and sell this covered call. The analysis also explores the possibility of the contract expiring worthless, offering a 1.42% premium boost, with current odds of this occurring estimated at 47%.
Enovis stock hits 52-week low at 25.43 USD
Enovis Corp's stock has dropped to a new 52-week low of $25.43, marking a 42.97% decline over the past year due to market trends and company-specific challenges. Despite this downturn, several firms like UBS, BTIG, and Freedom Capital Markets have initiated or maintained Buy ratings with price targets ranging from $41 to $50. The company has also announced leadership changes, appointing Oliver Engert as Chief Administrative Officer and Daniel A. Pryor transitioning from his executive role.
Enovis Names Davide Visentin as President of International Surgical Division
Enovis Corporation has appointed Davide Visentin as President of its International Surgical division. Visentin brings over two decades of global medical device leadership experience to the role, having previously held senior positions at Baxter International and Johnson & Johnson. He will oversee the continued growth and expansion of Enovis's surgical business outside of the United States.
A Look At Enovis (ENOV) Valuation After Naming Oliver Engert As Chief Administrative Officer
Enovis (ENOV) has appointed Oliver Engert as Chief Administrative Officer, a new role focusing on strategy, efficiency, and operational excellence, following a significant decline in shareholder returns over the past year. Despite recent stock pressure and a 20.94% share price decline over 90 days, the company is considered 45.7% undervalued with a narrative fair value of US$45.45 compared to its current price of US$24.66, based on future earnings potential and operational improvements. Investors are looking for clarity on execution and risk at the upcoming J.P. Morgan Healthcare Conference, as the valuation hinges on successful acquisition integration and managing external pressures like tariffs.
BTIG initiates Enovis stock with Buy rating, cites growth potential
BTIG initiated coverage on Enovis Corp (NYSE:ENOV) with a Buy rating and a $41.00 price target, citing the company's multi-segment orthopedic offerings, consistent organic revenue growth, and new product launches across Extremities, Hips, and Knees. The firm believes Enovis is undervalued at less than 8x next twelve months adjusted EBITDA, presenting an attractive entry point for investors. This positive outlook is supported by Enovis's strong Q3 2025 performance, recent appointments, and other analyst endorsements.
A Look At Enovis (ENOV) Valuation After Naming Oliver Engert As Chief Administrative Officer
Enovis (ENOV) has appointed Oliver Engert as Chief Administrative Officer, a strategic move following a period of significant shareholder returns decline. The company's stock is currently valued at US$24.66, with a narrative fair value of approximately US$45.45, suggesting it may be undervalued by 45.7%. The new appointment and ongoing operational excellence initiatives aim to improve earnings and free cash flow despite near-term headwinds.
Enovis stock hits 52-week low at 25.43 USD By Investing.com
Enovis Corporation's stock has plunged to a new 52-week low of $25.43 USD, marking a significant 42.97% decline over the past year due to market trends and company-specific issues. Despite this downturn, analysts from UBS, BTIG, and Freedom Capital Markets have maintained Buy ratings with price targets ranging from $41 to $50, citing updated sales projections and potential growth. The company also announced leadership changes, with Oliver Engert appointed Chief Administrative Officer and Daniel A. Pryor transitioning from an executive role.
Enovis Corporation (ENOV) Stock Analysis: Exploring the 68.66% Potential Upside for This Medical Device Innovator
Enovis Corporation (ENOV), a medical device innovator with a $1.54 billion market cap, shows a potential upside of 68.66% based on an average target price of $45.45, despite current stock volatility and negative short-term profitability metrics. The company primarily operates in Prevention and Recovery and Reconstructive segments, distributing products globally, reflecting a growth-centric investment opportunity for those willing to accept risk. Analysts remain largely bullish on ENOV due to its strong revenue growth and innovation strategy.
William Blair Maintains Enovis Corp(ENOV.US) With Buy Rating
William Blair analyst Brandon Vazquez has reiterated a Buy rating for Enovis Corp (ENOV.US). The analyst has a recorded success rate of 51.0% and an average return of 5.4% over the past year, according to TipRanks data. This information is intended for educational purposes and is not investment advice.
Las acciones de Enovis tocan mínimos de 52 semanas a 25,43 dólares
Las acciones de Enovis Corp (ENOV) han caído a un nuevo mínimo de 52 semanas, llegando a 25,43 dólares, lo que refleja una disminución del 42,97% en el último año. A pesar de este descenso, analistas de UBS, BTIG y Freedom Capital Markets han emitido calificaciones de "Compra" con precios objetivo que sugieren un potencial de recuperación. La empresa también ha realizado cambios en su dirección ejecutiva, nombrando a Oliver Engert como Director Administrativo y anunciando la salida reestructurada de Daniel A. Pryor.
Enovis stock hits 52-week low at 25.43 USD By Investing.com
Enovis Corp's stock has reached a new 52-week low of $25.43, marking a significant decline of 42.97% over the past year. Despite this downturn, analysts from UBS, BTIG, and Freedom Capital Markets have maintained or initiated Buy ratings, with price targets ranging from $41 to $50, citing updated sales projections and potential growth for the company. Enovis has also announced leadership changes, with Oliver Engert appointed as Chief Administrative Officer and Daniel A. Pryor transitioning from his executive officer role.
Enovis to Present at J.P. Morgan Healthcare Conference
Enovis (ENOV) announced its management team would present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 p.m. PST. The presentation was made available via live webcast and later through a replay and materials online. Despite a "Buy" analyst rating and a $41.00 price target, TipRanks’ AI Analyst, Spark, rates ENOV as "Neutral" due to financial performance challenges and bearish technical momentum, with significant risks remaining despite positive earnings call highlights.
Is Enovis (ENOV) Elevating Execution Risk Management With Its New Chief Administrative Officer?
Enovis (ENOV) recently appointed Oliver Engert as its first Chief Administrative Officer, a move aimed at enhancing strategy development, organizational efficiency, and operational excellence for the medical technology company. This appointment is expected to sharpen the company's execution of long-term plans, particularly its orthopedics portfolio and acquisition strategy, which has previously faced integration challenges. While the role aligns with improving efficiency, investors remain focused on integration risks and technology rollouts, especially given Enovis' history of multiple acquisitions.
Inside a medical tech company’s investor meetings at a health conference
Enovis (NYSE: ENOV), a medical technology company, announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 p.m. PST. A live audio webcast, presentation slides, and replay will be available on the company's website. This participation reinforces Enovis's ongoing engagement with institutional investors, following recent portfolio changes, leadership additions, and financial reporting including Q3 2025 net sales and a goodwill impairment.
Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Enovis Corporation announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12th, 2026, at 4:30 p.m. PST. A live audio webcast and presentation slides will be available on the company's investor relations website. Enovis is a global medical technology innovator focused on improving patient outcomes and restoring motion.
Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Enovis Corporation (NYSE: ENOV), a medical technology company, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. The company's management team will meet with investors and present on Monday, January 12th, 2026, at 4:30 p.m. PST. A live audio webcast, presentation slides, and replay will be available on their company website.
Enovis Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
Enovis Corporation announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 p.m. PST, with a live webcast available. The medical technology company aims to engage with investors, enhancing its visibility and demonstrating its commitment to transparency. This participation highlights Enovis's position as an innovation-driven firm, despite the announcement lacking specific financial forecasts or new product details.
Enovis Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
Enovis Corporation announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 p.m. PST. A live audio webcast and presentation slides will be available on the company's website. Enovis is a medical technology company focused on improving patient outcomes through innovative solutions.
A Look At Enovis (ENOV) Valuation After Creating A New Chief Administrative Officer Role
Enovis (ENOV) has appointed Oliver Engert as Chief Administrative Officer to enhance strategy, efficiency, and capital discipline following operational challenges. Despite recent share price weakness, the stock is considered significantly undervalued by analysts, trading at a large discount to a fair value of US$47. This move is seen as a potential leadership reset that could improve future growth and execution, although past goodwill impairment and lower revenue guidance are noted as risks.
A Look At Enovis (ENOV) Valuation After Creating A New Chief Administrative Officer Role
Enovis (ENOV) has appointed Oliver Engert as Chief Administrative Officer, aiming to sharpen its strategy and improve efficiency after recent operational challenges. Despite a 3.3% short-term share price return, its 1-year and 5-year returns are significantly down. Analysts believe Enovis is undervalued at US$27.92, with a fair value target of US$47, based on expected operational improvements and margin expansion, though goodwill impairment and lower revenue guidance present risks.
BTIG initiates Enovis stock with Buy rating, cites growth potential By Investing.com
BTIG initiated coverage on Enovis Corp (NYSE:ENOV) with a Buy rating and a $41.00 price target, seeing a 52% upside. The firm views Enovis as an undervalued multi-segment orthopedics company with consistent organic revenue growth and strong margins, presenting an attractive entry point for investors. This outlook is supported by recent strong Q3 2025 performance and new product launches across its segments.
